DesignQ Developer, Author at AdvanCell

News

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

Brisbane, Australia and Boston, USA – February 2, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company…

DesignQ Developer2 February 2026

News

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at…

DesignQ Developer2 December 2025

Presentations/Publications

AdvanCell presenting at the American Association for Cancer Research (AACR) Annual Meeting 2025

Preclinical evaluation and preliminary human imaging of a novel 212Pb-based, PSMA-targeted radioligand, 212Pb-ADVC001, for prostate…

DesignQ Developer28 April 2025

News

Pb212 PSMA vs Ac225 PSMA from biology to supply Alfred Morgenstern PhD Joint Research Centre Karlsruhe Germany

Source: UroToday PSMA & Beyond: Prof Alfred Morgenstern’s ‘212Pb-PSMA vs 225Ac-PSMA from Supply to Biology’…

DesignQ Developer21 April 2025

News

AdvanCell awarded $18M in Federal funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

AdvanCell proudly announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers…

DesignQ Developer14 April 2025

Presentations/Publications

TheraPb Phase Ib/IIa Dose Escalation and Expansion Study of [212Pb]Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer

Despite an increase in the number of approved therapies for metastatic castration- resistant prostate cancer…

DesignQ Developer13 February 2025

News

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the…

DesignQ Developer10 February 2025

News

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing Sydney, Australia – 3 February 2025…

DesignQ Developer3 February 2025

News

AdvanCell Commences Drug Product Manufacture from its Facility in Queensland, Australia

AdvanCell Commences Drug Product Manufacture from its Facility in Queensland, Australia October 8th, 2024, SYDNEY…

DesignQ Developer8 October 2024

News

AdvanCell Recognised in Good Design Award Australia 2024

AdvanCell Recognised in Australia’s International Good Design Awards for Excellence in Design and Innovation September…

DesignQ Developer20 September 2024

News

DesignQ Developer

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

AdvanCell presenting at the American Association for Cancer Research (AACR) Annual Meeting 2025

Pb212 PSMA vs Ac225 PSMA from biology to supply Alfred Morgenstern PhD Joint Research Centre Karlsruhe Germany

AdvanCell awarded $18M in Federal funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

TheraPb Phase Ib/IIa Dose Escalation and Expansion Study of [212Pb]Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell Commences Drug Product Manufacture from its Facility in Queensland, Australia

AdvanCell Recognised in Good Design Award Australia 2024

Latest News

Quick Links

Locations

Contact Us

Locations